Innovators and start-ups in healthcare and biotech are experts in their innovation’s scientific and technical domain but often struggle with navigating the complex world of the healthcare industry.
If you want to objectively show the advantages and competitiveness of your innovation to potential investors, future users, (reimbursement) payers or even the media, you can greatly benefit from Mercury Pharmaceuticals’s Health Innovation Assessment solution.
By making use of robust methods to collect and analyse data, Health Innovation Assessment (HIA) aims to comprehensively assess the added value of (bio-)medical and healthcare innovations. HIA takes into account true multi-stakeholder perspectives on value assessment and the realm of marketplace decision making.
Clinical trials are very important as it allow us to evaluate the effectiveness of new drugs, new devices, preventative strategies or treatment strategies. It also enables us to discover better ways for patients' care.
- Learn more
Our mission remains constant as we endeavor to deliver novel medicines to patients with cancer, treating solid tumors with high unmet medical needs in well-defined patient populations that are currently not well supported.
- Learn more
Whether you're looking to manufacture toxicology batches or cGMP material for clinical trials, we can help you expedite molecules to clinic with full transparency.
- Learn more
31
Dec 2025
In a new study, Christine Agdestein has surveyed several aspects of the postnatal check-up. Agdestein is a specialist in general practice and a general practitioner, and is currently a PhD candidate at the Norwegian University of Science and Technology (NTNU). The research project is part of her PhD.
31
Dec 2025
In the realm of modern medicine, RNA-based therapies have emerged as a promising avenue, with significant advancements in metabolic diseases, oncology, and preventive vaccines. A recent article published in Engineering titled "The Future of AI-Driven RNA Drug Development" by Yilin Yan, Tianyu Wu, Honglin Li, Yang Tang, and Feng Qian, explores how artificial intelligence (AI) can revolutionize RNA drug development, addressing current limitations and offering new opportunities for innovation.
31
Dec 2025
A recent study published in Engineering has shed light on the transmission and epidemiological trends of tmexCD1-toprJ1-positive Klebsiella pneumoniae across various ecological niches, highlighting the potential threat this antibiotic-resistant bacterium poses to global public health.
31
Dec 2025
Plastic pollution does more than litter landscapes and oceans. According to a new perspective article published in Biocontaminant, viruses living on plastic surfaces may play an underrecognized role in spreading antibiotic resistance, raising concerns for environmental and public health worldwide.